SDHB系统
SDHA
琥珀酸脱氢酶
副神经节瘤
免疫组织化学
嗜铬细胞瘤
生物标志物
生物
癌症研究
内科学
突变
内分泌学
医学
酶
病理
基因
种系突变
生物化学
作者
Cristóbal Bernardo‐Castiñeira,Inés Sáenz‐de‐Santa‐María,Nuria Valdés,Aurora Astudillo,Milagros Balbín,Ana S. Pitiot,Paula Jiménez‐Fonseca,Bartolomé Scola,Isabel Tena,María‐José Molina‐Garrido,María‐Agustina Sevilla,Elena Beristein,Lluís Forga,Carles M. Villabona,Josep Oriola,Irene Halperín,Carlos M. Suarez,María‐Dolores Chiara
出处
期刊:Head & neck
[Wiley]
日期:2018-12-14
卷期号:41 (1): 79-91
被引量:8
摘要
BACKGROUND: Succinate dehydrogenase subunit B (SDHB) immunohistochemistry was considered a valuable tool to identify patients with inherited paraganglioma/pheochromocytoma (PGL/PCC). However, previous studies jointly analyzed 2 related but clinically distinct entities, parasympathetic head and neck paragangliomas (HNPGLs) and sympathetic PCCs/PGLs. Additionally, a role for hypoxia inducible factor-1α (HIF-1α) as a biomarker for succinate dehydrogenase (SDHx)-mutated tumors has not been studied. Here, we evaluated the utility of SDHB/HIF-1α proteins in HNPGLs and PCCs/PGLs as clinically useful biomarkers. METHODS: The SDHB/succinate dehydrogenase subunit A (SDHA)/HIF-1α immunohistochemistry analysis was performed in 158 genetically defined patients. RESULTS: Similarly to PCCs/PGLs, SDHB immune-negativity correlated with SDHx-mutations in HNPGLs (P < .0001). The HIF-1α stabilization was associated with SDHx-mutations in HNPGLs (P = .020), not in PCCs/PGLs (P = .319). However, 25% of SDHx-HNPGLs lacked HIF-1α positive cells. CONCLUSION: As in PCCs/PGLs, SDHB immunohistochemistry in HNPGLs is a valuable method for identification of candidates for SDHx-genetic testing. On the contrary, although SDHx mutations may favor HIF-1α stabilization in HNPGLs, this is not a clinically useful biomarker.
科研通智能强力驱动
Strongly Powered by AbleSci AI